References
- Hou S N, Bushinsky D A, Wish J B, Cohen J B, Harington J B. Hospital acquired renal insufficiency: a prospective study. Am J Med 1983; 74: 254–256
- Tepel M, van der Giet M, Schwartzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic contrast agent‐induced reductions in renal function by acetylcysteine. N Engl J Med 2000; 343: 180–184, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Almén T. Visipaque—a step forward. A historical review. Acta Radiol 1995; 36(suppl. 399)2–18
- Jakobsen J A, Lundby B, Kristoffersen D T, Borch K W, Hald J, Berg K J. Evaluation of renal function with delayed CT after injection of nonionic monomeric and dimeric contrast media in healthy volunteers. Radiology 1992; 182: 419–424, [PUBMED], [INFOTRIEVE]
- Grynne B, Nossen J O, Bolstad B, Borch K W. Main results of the first comparative studies on Visipaque. An overview of 18 clinical studies. Acta Radiol 1995; 36(suppl. 399)265–270
- Ueda J, Nygren A, Hansell P, Erikson U. Influence of contrast media on single nephron glomerular filtration rate in the kidney. A comparison between diatrizoate, iohexol, ioxaglate and iotrolan. Acta Radiol 1992; 33: 596–599, [PUBMED], [INFOTRIEVE]
- Heyman S N, Reichman J, Brezis M. Pathophysiology of radiocontrast nephropathy. A role for medullary hypoxia. Invest Radiol 1999; 34: 685–691, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Katzberg R W. Urography into the 21st century: new contrast media, renal handling, imaging characteristics, and nephrotoxicity. Radiology 1997; 204: 231–297
- Waybill M M, Waybill P N. Contrast media‐induced nephrotoxicity: identification of patients at risk and algorithms for prevention. J Vasc Interv Radiol 2001; 12: 3–9, [PUBMED], [INFOTRIEVE], [CSA]
- Brezis M, Rosen S. Hypoxia of the renal medulla—its implication for disease. N Engl J Med 1995; 332: 647–655, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Dobrota M, Powell C J, Holtz E, Wallin A, Vik H. Biochemical and morphological effects of contrast media on the kidney. Acta Radiol 1995; 36(suppl. 399)196–203
- Berg K J. Nephrotoxicity related to contrast media. Scand J Urol Nephrol 2000; 34: 317–322, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Murphy S W, Barrett B J, Parfrey P S. Contrast nephropathy. J Am Soc Nephrol 2000; 11: 177–182, [PUBMED], [INFOTRIEVE], [CSA]
- Morcos S K, Thomsen H S, Webb J AW. Contrast media‐induced nephrotoxicity: a concensus report. Eur Radiol 1999; 9: 1602–1613, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Levy E M, Viscoli C M, Horwitz R I. The effect of acute renal failure on mortality. A cohort analysis. JAMA 1996; 275: 1489–1494, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Barrett B J, Carlisle E J. Meta‐analysis of the relative nephrotoxicity of high‐ and low‐osmolality iodinated contrast media. Radiology 1995; 188: 171–178
- Cochran S T, Wong W S, Roe D J. Prediction of angiography‐induced acute renal function impairment: clinical risk model. Am J Radiol 1983; 141: 1027–1033
- Rudnick M R, Goldfarb S, Wexler L, Ludbrook P A, Murphy M J, Halpern E F, Hill J A, Winniford M, Cohen M B, VanFossen D B. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. Kidney Int 1995; 47: 254–261, [PUBMED], [INFOTRIEVE]
- Lautin E M, Freeman N J, Schoenfeld A H, Bakal C W, Haramiti N, Friedman A C, Lautin J L, Braha S, Kadish E G, Sprayregen S, Belizon I. Radiocontrast‐associated renal dysfunction: incidence and risk factors. Am J Radiol 1991; 157: 49–58
- Manske C L, Sprafka J M, Strony J T, Wang Y. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med 1990; 89: 615–620, [PUBMED], [INFOTRIEVE], [CROSSREF]
- McCullough P A, Wolyn R, Rocher L L, Levin R N, O'Neill W W. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997; 103: 368–375, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Talierco C P, Vliestra R E, Ilstrup D M, Burnett J C, Menke K K, Stensrud S L, Holmes D R. A randomized comparison of the nephrotoxicity of iopamidol and diatrizoate in high risk patients undergoing cardiac angiography. J Am Coll Cardiol 1991; 17: 384–390, [CSA]
- Weisberg L J, Kurnik P B, Kurnik B RC. Risk of radio‐contrast nephropathy in patients with and without diabetes mellitus. Kidney Int 1994; 45: 259–265, [PUBMED], [INFOTRIEVE]
- Lautin E M, Freeman N J, Schoenfeld A H, Bakal C W, Haramiti N, Friedman A C, Lautin J L, Braha S, Kadish E G, Sprayregen S, Belizon I. Radiocontrast associated renal dysfunction: a comparison of lower‐osmolality and conventional high‐osmolality contrast media. Am J Radiol 1991; 157: 59–65
- Barrett B J, Parfrey P S, Vavasour H M, McDonald J, Kent G, Hefferton D, O'Dea F, Stone E, Reddy R, McManamon P J. Contrast nephropathy in patients with impaired renal function: high versus low osmolar media. Kidney Int 1992; 41: 1274–1279, [PUBMED], [INFOTRIEVE]
- Clauss W, Dinger J, Meissner C. Renal tolerance of iotrolan 280—a meta‐analysis of 14 double‐blind studies. Eur Radiol 1995; 5: S79–S84
- Chalmers N, Jackson R W. Comparison of iodixanol and iohexol in renal impairment. Br J Radiol 1999; 72: 701–703, [PUBMED], [INFOTRIEVE], [CSA]
- Aspelin P, Aubry P, Fransson S G, Strasser R, Willenbrock R, Berg K J. Nephrotoxicity in high risk patients. A double blind randomized multicenter study of iso‐osmolar and low‐osmolar nonionic contrast media. The NEPHRIC study. N Engl J Med 2003; 348: 491–499, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Mc Carthy C S, Becker J A. Multiple myeloma and contrast media. Radiology 1992; 183: 519–521
- Solomon R, Werner C, Mann D, D'Elia J, Silva P. Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994; 331: 1416–1420, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Trivedi H S, Moore H, Nasr S, Aggarwal K, Agrawal A, Goel P, Hewett J. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract 2003; 93: C29–C34, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Mueller C, Buerkle G, Buettner H J, Petersen J, Perruchoud A P, Eriksson U, Marsch S, Roskamm H. Prevention of contrast media‐associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002; 162: 329–336, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Erley C M, Duda S H, Rehfuss D, Scholtes B, Bock J, Müller C, Osswald H, Risler T. Prevention of radiocontrast‐media‐induced nephropathy in patients with pre‐existing renal insufficiency by hydration in combination with the adenosine antagonist theophylline. Nephrol Dial Transplant 1999; 14: 1146–1149, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Weinstein J M, Heyman S, Brezis M. Potential deleterious effect of furosemide in radiocontrast nephropathy. Nephron 1992; 62: 413–415, [PUBMED], [INFOTRIEVE]
- Erley C M. Does hydration prevent radiocontrast‐induced acute renal failure. Nephrol Dial Transplant 1999; 14: 1064–1066, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Heyman S N, Goldfarb M, Shina A, Karmeli F, Rosen S. N‐acetylcysteine ameliorates renal microcirculation; studies in rats. Kidney Int 2003; 63(2)634–641, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Baker C SR, Wragg A, Kumar S, DePalma R, Baker L RI, Knight C J. A rapid protocol for the prevention of contrast‐induced renal dysfunction: the RAPPID study. J Am Coll Cardiol 2003; 41: 2114–2118, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Diaz‐Sandoval L J, Kosowsky B D, Losordo D W. Acetylcysteine to prevent angiography‐related renal tissue injury (the APART trial). Am J Cardiol 2002; 89: 356–358, [CROSSREF], [CSA]
- Kay J, Chow W H, Chan T M, Lo S K, Kwok O H, Yip A, Fan K, Lee C H, Lam W F. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention. A randomized controlled trial. JAMA 2003; 289: 553–558, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Allaquaband S, Tumuluri R, Malik A M, Gupta A, Volkert P, Shalev Y, Bajwa T K. Prospective randomized study of N‐acetylcysteine, fenoldopam, and saline for prevention of radiocontrast‐induced nephropathy. Catheter Cardiovasc Interv 2002; 57: 279–283, [CROSSREF], [CSA]
- Durham J D, Caputo C, Dokko J, Zaharakis T, Pahlavan M, Keltz J, Dutka P, Marzo K, Maeska J K, Fishbane S A. Randomized controlled trial of N‐acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 2002; 62: 2202–2207, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Briguori C, Manganelli F, Scarpato P, Elia P P, Golia B, Reviezzo G, Lepore S, Librera M, Villari B, Colombo A, Ricciardelli B. Acetylcysteine and contrast agent‐associated nephrotoxicity. J Am Coll Cardiol 2002; 40: 298–303, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kini M S, Mitre C A, Kin M, Kamran M, Reich D, Sharma S K. Changing trends in incidence and predictors of radiographic contrast nephropathy after percutaneous coronary intervention with the use of fenoldopam. Am J Cardiol 2002; 89: 999–1002, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Waaler A, Svaland M, Fauchald P, Jakobsen J A, Kolmannskog F, Berg K J. Elimination of iohexol, a low osmolar non‐ionic contrast medium by hemodialysis in patients with chronic renal failure. Nephron 1990; 56: 81–85, [PUBMED], [INFOTRIEVE]
- Lehnert T, Keller E, Gondolf K, Schäffner T, Pavenstädt H, Schollmeyer P. Effect of hemodialysis after contrast medium administration in patients with severe renal insufficiency. Nephrol Dial Transplant 1998; 13: 358–362, [PUBMED], [INFOTRIEVE], [CSA]
- Sterner G, Frennby B, Kurkus J, Nyman U. Does post‐angiographic hemodialysis reduce the risk for contrast medium nephropathy. Scand J Urol Nephrol 2000; 34: 324–327